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Background: Schwannomas are the most common neurofibromatosis type 2 (NF2)-associated tumors with
significant phenotypic heterogeneity in patients. The most severe subtype has an early and rapid progression and
the mild type has a later onset and a less aggressive course. The aim of this study was to elucidate the underlying
molecular differences between these groups. We compared the gene expression pattern between patients with
early to late age of onset.
Results: A gene signature of 21 genes was constructed to differentiate between early-onset and late-onset patients.
We confirmed these results by real-time PCR for SNF1LK2, NGFRAP1L1 (BEX 5), GMNN, and EPHA2.
Conclusion: Genes identified here may be additional aberrations in merlin-depleted cells that govern the disease
onset. A significant number of these genes have been suggested as having a role in carcinogenesis and are used as
biomarkers for prognosis in several other cancers. The role of these genes in NF2 carcinogenesis and their potential
as biomarkers or drug target are worthwhile exploring.
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Neurofibromatosis type 2 (NF2) is an autosomal do-
minant disorder that predisposes affected individuals to
several types of cerebral and spinal tumors [1]. Epide-
miological studies place the incidence of NF2 at 1 in
25,000 live births [2]. The current treatment of NF2 is
surgery and/or radiation therapy. However, there is no
current safe therapeutic agent available at this time. Bi-
lateral vestibular schwannomas (BVS) are the most com-
mon of NF2-associated tumors [3]. The consequences of
a vestibular schwannomas (VS) are numerous, including
dizziness, imbalance, tinnitus, hearing loss progressing
to deafness, facial nerve paralysis, brainstem compres-
sion, and, if left untreated, death.
Mutations of the NF2 gene are thought to be the pri-
mary cause of this disease. Various types of mutations
have been identified, among them single-base substitu-
tions, insertions, and deletions [4]. The NF2 gene prod-
uct, merlin, functions as a signal transduction pathway* Correspondence: mehrian@usc.edu
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unless otherwise stated.regulating cell-to-cell and cell matrix interactions. Merlin
has been demonstrated to exert its antiproliferative effect
by impact on several intracellular signaling pathways: inhib-
ition of phosphatidylinositol 3-kinase (PI3-kinase), through
binding to PI3-kinase enhancer, long form (PIKE-L) [5],
modulation of the RAS/RAC oncogenic pathways [6], in-
hibition of the mitogen-activated protein kinase (MAPK)
pathways [7] and repression of PAK-induced cyclin D1 ex-
pression [8]. Merlin regulates the MAPK signaling path-
way by blocking the Cdc42-MLK3 interaction and MLK3
activity inhibition [9]. Furthermore, inactivation of merlin
induces oncogenic gene expression, hyperproliferation,
and tumorigenicity by releasing the inhibition of E3 ubi-
quitin ligase CRL4 (DCAF1) in the nucleus [10].
Since the disease has a variable presentation, with the
severe subtype having an early and rapid progression
and the milder type having a later onset and a less ag-
gressive course, the diagnosis and management of these
patients present a unique challenge [11]. Studies have in-
dicated that a truncating NF2 mutation (nonsense and
frameshift) is linked with the more severe form of NF2
[3]. The more severe form is particularly virulent, with
unrelenting growth of schwannomas and meningiomastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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lysis, and death by the age of 40. The mild form of NF2
is less debilitating. The schwannomas may remain the
same size for years, few meningiomas will develop. The
patient may not develop symptoms until later in life and
will have fewer disabilities [3].
There is considerable variability in growth rates of VS
in patients with NF2, but they tend to be higher in pa-
tients who are younger at onset of signs or symptoms
[12]. The most important predictors of disease severity
are age at diagnosis and age at onset of symptoms. The
average age of onset is 18 to 24 years. Almost all affected
individuals develop bilateral vestibular schwannomas by
age 30 years. Vestibular schwannomas are much less com-
mon in children than adults [13]. There are age-specific
risks of NF2 to an offspring of a patient. Patient presenting
with BVS <20 years 29.3% and patient presenting with
asymmetric disease after 40 years 5.5% [14]. Patients of
ages 35 years and below show higher p53 phosphorylation
compared to the tumors of older patients [15].
The development of microarray tools assists effective,
current, and comprehensive understanding of complex
diseases including cancer [16]. Differences in gene ex-
pression between schwannomas or between schwannoma
cells from NF2 patients and normal human primary
schwann cells previously examined do not confer age
impact [17-19]. Here, we report whole genome gene ex-
pression variation in NF tumors differing in age of onset.Figure 1 Volcano plot of early- and late-onset tumors.Improved understanding of these molecular differences
may allow elucidation of age-dependent onset etiology,
novel molecular markers for prognosis, and new thera-
peutic targets for neurofibromatosis.
Results and discussion
We analyzed the transcriptome of VS samples from
early-onset patients and late-onset patients. The results
were summarized in a volcano scatter plot (Figure 1)
that summarizes both fold change and t test criteria.
The negative log10-transformed p values from the gene-
specific t test was plotted against the log2 fold change
between early and late onset. Genes with statistically sig-
nificant differential expression according to the gene-
specific t test lie above the horizontal threshold line.
Genes with large fold change values lie outside the
pair of vertical threshold lines. Twenty one signifi-
cantly differentially expressed genes are identified by
fold change >1.5 and p value <0.01: ANLN, NAV3,
ZNF718, PSCD3, C180rf54, C10rf79, XPO1, GMNN,
WHSC1, EPHA2, SNF1LK2, NGFRAP1L1, ELL2, SYTL3,
KCNK17, IGLV1-44, PID1, RGN, PTPN1, ZNF331, and
RNF19A (Table 1). Figure 2 illustrates the hierarchical ex-
pression of these genes for the two groups. The genes are
clustered according to their relative expression in each
group. Green color represents genes that have relatively
low expression and red color represents genes that have
relatively high expression. Finally, we utilized quantitative
Table 1 List of age-dependent differentially expressed genes
Gene symbol Fold change p value Function Activity Role in cancer
ANLN 3.55 0.0053 Actin-binding protein Overexpressed in pancreatic carcinoma
NAV3 1.65 0.0099 G Neuron growth, regeneration Neural tumorigenesis
ZNF718 1.61 0.0064 Zinc finger protein Associated with prostate cancer
PSCD3 1.59 0.0035 T Protein sorting and membrane trafficking
C180rf54 1.57 0.0047 Overexpressed in multiple cancers
XPO1 1.56 0.0079 T/K Nuclear protein transport export
C10rf79 1.56 0.0065
GMNN 1.55 0.0032 G Proliferation marker Correlated with poorer clinical outcome
WHSC1 1.51 0.006 Regulation of Wnt pathway Expression increases with ascending glioma
proliferation activity
EPHA2 1.51 0.0073 K Tyrosine Kinase Overexpressed in many types of cancer
SNF1LK2 −2.03 0.0055 K Serine/Threonine kinase Correlated with ovarian cancer poor survival
NGFRAP1L1 (BEX5) −1.8 0.0009 G Nerve growth factor receptor-associated May be a tumor suppressor in VS
ELL2 −1.8 0.0031 Suppress canonical Wnt signaling ELL translocations in malignancies.
SYTL3 −1.79 0.0053 T Vesicular trafficking
KCNK17 −1.76 0.006 Potassium channel Expressed abnormally in many cancer types
IGLV1-44 −1.68 0.0057
PID1 −1.62 0.0084 Glucose transport inhibitor
RGN −1.59 0.0052 Suppresses cell proliferation Lost in breast and prostate cancer
PTPN1 −1.57 0.0076 K/G Cell growth
ZNF331 −1.53 0.0074 D Induces apoptosis
RNF19A −1.52 0.0025 D Neuronal cell death
T transport, K kinase, G growth, D death.
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Figure 2 Heat map on age onset-dependent gene expression.
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the most potential future application according to the role
they play in other cancers: SNF1LK2, NGFRAP1L1 (BEX
5), GMNN, and EPHA2 (Figures 3 and 4). In fact, RT-
PCR confirmed the results for these genes and t test for
all genes were significant at p value <0.005 (SNF1LK2
p value 2 × 10−7, NGFRAP1L1 (BEX5) p value 0.0002,
GMNN p value 0.0009, and EPHA2 p value 9 × 10−6).
Although the NF2 locus on chromosome 22 is associ-
ated with the formation of vestibular schwannomas, it is
clear that in addition to merlin gene, there are a variety
of other genes whose ‘dysregulation’ may eventually re-
sult in tumor formation. Comparison of gene expression
between early- and late-onset specimens which all are
merlin depleted provides a valuable insight into the mo-
difications of these genes. Gene expression analysis of
NF2 samples resulted in 21 genes that differentiate early-
onset tumors from late-onset tumors (Table 1). Some of
them are widely involved in nervous system activities and
have been associated with cancer as described below and
summarized in Table 2.
Ten of the 21 genes we identified fall into four broad
functional categories (Table 1): protein transport (genes
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Figure 3 SNF1LK2 (A) and BEX5 (B) quantitative real-time
PCR validation.
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Figure 4 EPHA2 (A) and GMNN (B) quantitative real-time
PCR validation.
Table 2 Proposed applicable uses of differentially
expressed genes
Gene Other
cancer
Drug
target
Outcome
prediction
To be
defined
EPHA2 Y Y Y
XPO1 Y Y Y
SNF1LK2 Y Y Y
NAV3 Y Y Y
KCNK17 Y Y Y
ZNF331 Y Y Y
GMNN Y Y
ZNF718 Y Y
WHSC1 Y
ANLN Y
PSCD3 Y
RGN Y
ELL2 Y
PTPN1 Y
BEX5 Y
SYTL3 Y
RNF19A Y
P1D1 Y
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and dephosphorylation (XPO1, EPHA2, and SNF1LK2),
cell growth (NAV3, GMNN, and NGFRAP1L1), and cell
death (ZNF331 and RNF19A). The latter two are par-
ticularly relevant to cancerous growth and the first two
may underpin it as well. Additional cellular functions
and cancer phenotypes are also listed in Table 1. Fur-
thermore, some, at least 14 (EPA, XPO, SNF1LK, NAV3,
KCNK17, ZNF331, GNMM, ZNF718, WHSC1, ANLN,
PSCD3, RGN, ELL2, and PTPN1) of the 21 genes, have
been reported to be involved in cancers (Table 1).
We further grouped the 21 genes we identified into 4
subgroups according to their potential role in NF2: in
carcinogenesis, as biomarker, as drug target, or potential
for clinical outcome prediction. This was according to
other studies findings for each gene above. Another group
was constructed from genes that their role in cancer has
not been indicated yet (Table 2).
In summary, we report here a gene signature compris-
ing 21 genes that characterize the clinically important
age at onset in NF2 patients. Interestingly, many of these
genes have known or at least inferred functions which
may lead to a more complete molecular understanding
of the age-based pathogenic differences in NF2 in the
future. Such data may, in turn, lead to improved pre-
symptomatic diagnoses and personalized age-focused
treatment.
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There is great phenotypic difference between early and
late onset in NF2. Our data indicate that these groups
have distinct gene expression signatures. Most of the dif-
ferentiating genes have already been shown to have im-
portant roles in other cancers. Thus, they may also have
a role in VS NF2 patients. Moreover, these genes may be
involved in pathogenesis, used as potential age-oriented
biomarkers and treatment targets. Our gene lists will
provide fertile ground for testing novel hypotheses on dis-
ease mechanism, pathogenesis, and therapeutic targets.
Methods
Thirty-seven samples from human tumor (schwannomas)
tissues were obtained at the time of surgery in accordance
with applicable human ethics regulations (USC IRB proto-
col # 97–157) and snap frozen in liquid nitrogen. Tumor
specimens were divided into two groups (young and old)
according to the patient's age of onset. The young-onset
group included 21 specimens from patients whose age
of onset was less than 16 years old (ranging from 7 to
16 years old). The old-onset group included 16 specimens
from patients whose age of onset was 30 years and older
(ranging from 30 to 67 years old). The average age of the
young group was 12 years old. The average age of the old
group was 43 years. RNA was extracted and cRNA were
hybridized to Human Genome U133 Plus 2.0 Array
(Affymetrix) for analysis of over 47,000 transcripts.
The detailed protocol for the sample preparation and
microarray processing is available from Affymetrix at
www.affymetrix.com (Santa Clara, CA, USA). For real-time
PCR, total RNA was extracted and RT-qPCR was per-
formed in the DNA Engine Opticon 2 Continuous Fluores-
cence Detection System (Bio-Rad, Hercules, CA, USA).
Data analysis
The Bioconductor limma package [20] was used to pre-
process the expression data from Human Genome U133
Plus 2.0 Affymetrix Array. To remove batch effects, the
complete dataset were normalized by RMA. Before doing
statistical analysis, we filter the probe sets by present/
absent calls using the Wilcoxon signed rank-based al-
gorithm. Out of 54,675 probes, 42,339 were kept and
the remaining ones were removed as ‘Absent’ to reduce
false positive rate. We identified differentially expressed
gene list by fitting linear models to the normalized expres-
sion values. The empirical Bayes shrinkage was applied
to t statistics using the limma package in Bioconductor.
Because patient subtypes were still observed after RMA
normalization, balanced samples from the same subtype
were selected to identify significantly differentially ex-
pressed genes and to reduce the potential of small-sample
artifacts. In general, selected genes have greater than 1.5
fold change and less than 0.01 p value.The analysis of RT-PCR is as follows: Sample RNA
was processed in triplicate with serial dilutions of Human
Universal Reference RNA (Stratagene, La Jolla, CA, USA)
on the same 96-well plate. Standard curves were const-
ructed from the Universal RNA wells with arbitrary units
of 1 unit equivalent to 1 pg of Universal RNA. Results
were plotted as units per nanogram of RNA. Graphically,
the middle line of the bar represents mean, bar size cor-
responds to the difference between lower quartile and
upper quartile, and error bars represent the range of the
raw data. t test p values were calculated for each differen-
tiating gene.
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